PDLIM7 and neuroblastoma: This study aimed to develop a prototype innovative qPCR assay based on utilizing the unique features and innovative combination of the “gap-filling mutant primer” with “multi-points degenerative blocker” technology to detect EBV LMP1 30 bp deletion (genetic biomarker) from a less invasive WB sample and from NB sample from NPC patients.